GPCR NATIVE COMPLEX
DEAD

Serial Number

97148593

Owner

Septerna, Inc.

Attorney

Shane Rumbaugh

Filing Date

Nov 30, 2021

Add to watchlist:

No watchlists yet
View on USPTO

GPCR NATIVE COMPLEX Trademark

Serial Number: 97148593

GPCR NATIVE COMPLEX is a trademark filed by Septerna, Inc. on November 30, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Septerna, Inc. (3 trademarks)

250 East Grand Ave., Suite 65
San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

November 30, 2021

Registration Date

Not Registered

Goods & Services

Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for use in medical research

Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific research use; chemical reagents for use in genetic research

Providing a website featuring information about the treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

Bio-technology and scientific services, namely, research, and production and development services relating to bio-technology and science, namely, G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical research and development; Scientific and technological services, namely, biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research services, namely, treating therapeutic targets through chemical and biochemical preparations

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 21, 2023 MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 20, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 20, 2023 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 20, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 20, 2023 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
May 1, 2023 GNFN
FINAL REFUSAL E-MAILED
May 1, 2023 GNFR
FINAL REFUSAL WRITTEN
May 1, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 13, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 13, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 13, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 13, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 3, 2021 NWOS
NEW APPLICATION ENTERED
Dec 3, 2021 NWAP